Lab
Cedar Diagnostics, LLC
Cedar Diagnostics, LLC was paid $655K by Medicaid between Jan 2018 and Feb 2021, across 70 billing codes. Its largest line is 82306, Vitamin D; 25 hydroxy, includes fraction(s), if performed — 9.4% of everything it billed.
33Billing provider infoCEDAR DIAGNOSTICS, LLC
CORTEZ, CO 81321
CORTEZ, CO 81321
33aNPI1386895969assigned 10/01/2008
33bProvider typeClinical Medical Laboratory
28Total paid$655K
24GClaims46,596
24DCodes billed70
24AFirst – last monthJan 2018 – Feb 2021
Compared with peers
Next to other Clinical Medical Laboratory providers in Colorado
Rank by total paid#27 of 91
Median peer was paid$53K
This provider vs. median12×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,252 | $179K | |
| 2019 | 17,107 | $249K | |
| 2020 | 17,232 | $223K | |
| 2021 | 2,005 | $4K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 9.4% | 2,232 | 2,129 | $61K |
| 80050 | General health panel | 9.1% | 1,538 | 1,491 | $59K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 7.2% | 1,017 | 937 | $47K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.7% | 1,017 | 939 | $31K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 4.6% | 1,743 | 1,671 | $30K |
| 84443 | Thyroid stimulating hormone (TSH) | 4.5% | 1,768 | 1,685 | $30K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.3% | 3,802 | 3,524 | $28K |
| 86780 | 3.1% | 1,553 | 1,484 | $20K | |
| 80061 | Lipid panel | 3.0% | 1,608 | 1,552 | $20K |
| 86769 | 3.0% | 579 | 517 | $20K | |
| 88142 | 2.9% | 811 | 769 | $19K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.8% | 2,013 | 1,935 | $18K |
58 more codes
| 84481 | 2.8% | 1,056 | $18K | |
| 87088 | 2.6% | 2,282 | $17K | |
| 80053 | Comprehensive metabolic panel | 2.5% | 1,697 | $17K |
| 86762 | 2.3% | 1,016 | $15K | |
| 84403 | 2.2% | 589 | $14K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.2% | 434 | $14K |
| 87340 | 2.0% | 1,293 | $13K | |
| 82607 | 2.0% | 862 | $13K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 762 | $11K |
| 84439 | 1.4% | 1,158 | $9K | |
| 82670 | 1.4% | 337 | $9K | |
| 86803 | 1.3% | 617 | $9K | |
| 86850 | 1.3% | 1,288 | $8K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.2% | 280 | $8K |
| 83001 | 1.2% | 419 | $8K | |
| 87077 | 1.2% | 749 | $8K | |
| 86376 | <1% | 435 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 863 | $6K |
| 82950 | <1% | 943 | $5K | |
| 80320 | <1% | 257 | $4K | |
| 82105 | <1% | 232 | $4K | |
| 84702 | <1% | 258 | $4K | |
| 86901 | <1% | 1,130 | $4K | |
| 86900 | <1% | 1,129 | $4K | |
| 87186 | <1% | 653 | $3K | |
| 87070 | <1% | 223 | $3K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 46 | $3K |
| 82728 | <1% | 270 | $3K | |
| 84436 | <1% | 465 | $3K | |
| 80074 | <1% | 59 | $3K | |
| 84270 | <1% | 103 | $2K | |
| 83550 | <1% | 257 | $2K | |
| 83540 | <1% | 305 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 35 | $2K |
| 82746 | <1% | 178 | $2K | |
| 87480 | <1% | 48 | $1K | |
| 81001 | <1% | 325 | $1K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 59 | $985.68 |
| 87660 | <1% | 48 | $983.62 | |
| 83002 | <1% | 68 | $875.46 | |
| 84480 | <1% | 90 | $857.41 | |
| 86592 | <1% | 208 | $854.86 | |
| 84146 | <1% | 54 | $774.70 | |
| 82570 | <1% | 98 | $712.40 | |
| 87510 | <1% | 35 | $668.36 | |
| 86140 | <1% | 119 | $487.79 | |
| 83013 | <1% | 31 | $470.85 | |
| 86706 | <1% | 28 | $451.63 | |
| 84550 | <1% | 83 | $371.46 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 13 | $359.31 |
| 88304 | <1% | 26 | $310.27 | |
| 84144 | <1% | 14 | $287.56 | |
| 85651 | <1% | 75 | $269.99 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,710 | $112.55 |
| 82043 | <1% | 19 | $102.96 | |
| 84156 | <1% | 41 | $77.34 | |
| 85027 | <1% | 14 | $75.88 | |
| 81511 | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPAPAIOANU, ATHANASSIOS (PRESIDENT/CEO)
| Provider | Location | Paid |
|---|---|---|
| Asl-Den LLC | West Palm Beach, FL | $5.40M |
| App-Ecp, LLC | Wilson, NC | $2.05M |
| Lab Alliance LLC | Carrollton, TX | $460K |
| Path Alliance INC | Carrollton, TX | $238K |
| Alex R. Cudkowicz, M.D.,P.C. | Cortez, CO | $76K |
| App-Pbp, LLC | West Palm Beach, FL | $16K |
| Ariana Diagnostics, LLC | Nashville, TN | $11K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.